Drug updated on 11/16/2023

Dosage FormTablet (oral; 25 mg, 100 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies


  • For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Product Monograph / Prescribing Information

Document TitleYearSource
Lorbrena (lorlatinib) Prescribing Information.2021Pfizer Inc., New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of first-line treatments for patients with advanced anaplastic lymphoma kinase mutated, non–small cell cancer: A systematic review and network meta-analysis.2023ACS Journals
Comparative safety of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced anaplastic lymphoma kinase-mutated non-small cell lung cancer: Systematic review and network meta-analysis. 2023Lung Cancer
A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer. 2023Cancer Medicine
A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). 2023Pharmaeconomics
Cost Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK) Positive Non Small Cell Lung Cancer in Sweden. 2023Applied Health Economics and Health Policy
Assessment report: Lorviqua.2022EMA
Combined clinical and Pharmacoeconomic report: lorlatinib (Lorbrena) for ALK-positive locally advanced or metastatic non-small cell lung cancer.2022CADTH
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non‑small cell lung cancer: a systematic review and meta‑analysis. 2022Investigational New Drugs
ALK inhibitors in ALK-rearranged non-small cell lung cancer with and without brain metastases: systematic review and network meta-analysis.2022BMJ Open
Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer. 2022Cochrane Database of Systematic Reviews
Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in Asian and non-Asian patients: a systematic review and network meta-analysis.2021Cancers
Final clinical guidance report: lorlatinib (Lorbrena) for non-small cell lung cancer.2020CADTH
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer.2020NICE

Clinical Practice Guidelines